WHAT IS CCC?

Improving Care for Cardiovascular Disease in China (CCC) is a multi-year project focussed on improving compliance with evidence-based therapy for patients with ACS and AFib in almost 200 tertiary and secondary hospitals across China.

ADDRESSING THE COMPLIANCE GAP

- Only one third of the eligible NSTE-ACS patients received timely PCI according to the guidelines.
- Only 57.4% of patients with STEMI received acute reperfusion therapy.

WHAT'S THE PROGRAMME ACHIEVED SO FAR?

- 76% compliance rate in guideline-led care for ACS patients among those hospitals enrolled.
- Groundbreaking number of records in the system: 103,298 for ACS and 54,863 for AFib.
- Groundbreaking number of publications: 8 for ACS and 1 for AFib.

WHAT'S NEXT?

- Enhance communication between National Health Commission (NHC) on a national and local level by sharing project results.
- Strengthen transitions from hospital to home, improving patient adherence to medications and reducing the risk of secondary events.
- Replicate nationwide, to potentially improve outcomes for millions more patients.

WHO'S INVOLVED?

CCC is supported by funding from AstraZeneca, American Heart Association, and Chinese Society of Cardiology.

Expanding the use of guidelines & improving CV health through:

Data collection, Analysis, Feedback, Process improvement.


Document ID: Z4-17998 | Date of Preparation: August 2019 | Date of Expiry: August 2021.